Costs of bleeds relating to acute coronary syndrome therapies

Journal of Medical Economics

Volumn 13, Issue 2, 2010, Pages 236-240

  Bufe, Alexander ^a   Emile, Ferrari ^b   Drogoul, Laurent ^b   Guindo Soldevila, Josep ^c   Pasquale Giuseppe, Di ^d   Maddalena, Lettino ^e   Janzon, Magnus ^f   Brown, Ruth E ^g  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b PASTEUR HOSPITAL   (France)

^c Hospital Parc Taul   (Spain)

^d MAGGIORE HOSPITAL   (Italy)

^e Istituto di Ricovero e Cura a Carattere Scientifico di Diritto Pubblico   (Italy)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Acute coronary syndrome; Bleeds; Costs

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; HEMOGLOBIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD TRANSFUSION; COMORBIDITY; CONTROLLED STUDY; COST OF ILLNESS; DIAGNOSTIC PROCEDURE; FEMALE; FRANCE; GERMANY; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITAL DISCHARGE; HUMAN; INJECTION SITE BLEEDING; ITALY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; RETROSPECTIVE STUDY; SPAIN; SWEDEN;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; BLOOD TRANSFUSION; COMORBIDITY; EUROPE; FEMALE; FIBRINOLYTIC AGENTS; HEMOGLOBINS; HEMORRHAGE; HOSPITAL COSTS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PUNCTURES; RETROSPECTIVE STUDIES;

EID: 77953349556     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.488882     Document Type: Article

References (12)

1. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
2. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med Apr 6 2006;354:1464-1476
3. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med Aug 16 2001;345:494-502.
4. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998;338: 1498-1505.
5. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998;338:1488-1497.
6. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998; 339:436-443.
7. Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355: 1936-1942.
8. McMurray JJ, Andersson FL, Stewart S, et al. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2006; 27:1447-1458.
9. DKG-NT Band I. Tarif der Deutschen Krankenhausgesellschaft für die Abrechnung erbrachter Leistungen und für die Kostenerstattung vom Arzt an das Krankenhaus. 31., überarbeitete Auflage, 1. März 2007. Ed. Deutsche Krankenhausgesellschaft, Verlag W. Kohlhammer.
10. Soikos. Base de datos de costes sanitarios. Version 2.2. Barcelona: Soikos, 2005.
11. National outpatient tariffs, Italy, 1996. http://www.ministerosalute. it/programmazione/normativa/sezNormativa.jsp?label=tar
12. Vårddag, Sluten Vård, Kardiologi Malmö.